claudin-2 Inhibitors
The chemical class known as claudin-2 inhibitors encompasses a diverse group of compounds that influence the dynamics of tight junctions through intricate cellular signaling pathways. NSC23766, a Rac1-specific inhibitor, indirectly modulates claudin-2 by disrupting the Rho GTPase signaling pathway. Rac1's involvement in actin cytoskeleton remodeling and tight junction regulation is crucial, and NSC23766's inhibition alters the dynamic regulation of claudin-2, impacting its localization and function within tight junctions. Bumetanide, a loop diuretic, indirectly influences claudin-2 by targeting the Na+-K+-2Cl- cotransporter (NKCC2). By altering ion gradients, bumetanide affects the paracellular permeability and localization of claudin-2 within tight junctions. Y-27632, a selective Rho-associated protein kinase (ROCK) inhibitor, disrupts claudin-2 dynamics by targeting the ROCK signaling pathway. Inhibition of ROCK alters the dynamic regulation of claudin-2, impacting its localization and function within tight junctions.
ML-7, a myosin light chain kinase (MLCK) inhibitor, indirectly influences claudin-2 by disrupting the MLCK signaling pathway. The alteration in actin cytoskeleton remodeling and tight junction regulation highlights the intricate relationship between MLCK inhibition and claudin-2 dynamics. Flufenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), indirectly modulates claudin-2 by targeting the calcium-sensing receptor (CaSR) signaling pathway. Inhibition of CaSR by flufenamic acid alters ion gradients, affecting the paracellular permeability and localization of claudin-2 within tight junctions. These inhibitors collectively provide a comprehensive view of the interconnected regulatory networks governing claudin-2 dynamics, offering molecular insights into potential avenues for targeted interventions to modulate tight junction integrity. The indirect modulation of claudin-2 by these compounds emphasizes the complexity of tight junction regulation and highlights potential strategies for conditions involving tight junction dysfunction.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
NSC 23766 | 733767-34-5 | sc-204823 sc-204823A | 10 mg 50 mg | $151.00 $609.00 | 75 | |
NSC23766, a Rac1-specific inhibitor, indirectly modulates claudin-2 by targeting the Rho GTPase signaling pathway. Rac1 is involved in actin cytoskeleton remodeling and tight junction regulation. Inhibition of Rac1 by NSC23766 disrupts the dynamic regulation of claudin-2, impacting its localization and function within tight junctions. | ||||||
Bumetanide (Ro 10-6338) | 28395-03-1 | sc-200727 sc-200727A | 1 g 5 g | $109.00 $228.00 | 9 | |
Bumetanide, a loop diuretic, indirectly influences claudin-2 by targeting the Na+-K+-2Cl- cotransporter (NKCC2). NKCC2 is involved in ion transport and tight junction regulation. Bumetanide's inhibition of NKCC2 alters ion gradients, affecting the paracellular permeability and localization of claudin-2 within tight junctions. | ||||||
Y-27632, free base | 146986-50-7 | sc-3536 sc-3536A | 5 mg 50 mg | $186.00 $707.00 | 88 | |
Y-27632, a selective Rho-associated protein kinase (ROCK) inhibitor, indirectly modulates claudin-2 by disrupting the ROCK signaling pathway. ROCK is involved in actin cytoskeleton organization and tight junction regulation. Inhibition of ROCK by Y-27632 alters the dynamic regulation of claudin-2, impacting its localization and function within tight junctions. | ||||||
ML-7 hydrochloride | 110448-33-4 | sc-200557 sc-200557A | 10 mg 50 mg | $91.00 $267.00 | 13 | |
ML-7, a myosin light chain kinase (MLCK) inhibitor, indirectly influences claudin-2 by disrupting the MLCK signaling pathway. MLCK is involved in actin cytoskeleton remodeling and tight junction regulation. Inhibition of MLCK by ML-7 alters the dynamic regulation of claudin-2, impacting its localization and function within tight junctions. | ||||||
Flufenamic acid | 530-78-9 | sc-205699 sc-205699A sc-205699B sc-205699C | 10 g 50 g 100 g 250 g | $27.00 $79.00 $154.00 $309.00 | 1 | |
Flufenamic acid, a nonsteroidal anti-inflammatory drug (NSAID), indirectly modulates claudin-2 by targeting the calcium-sensing receptor (CaSR) signaling pathway. CaSR is involved in ion transport and tight junction regulation. Inhibition of CaSR by flufenamic acid alters ion gradients, affecting the paracellular permeability and localization of claudin-2 within tight junctions. | ||||||
ML-9 | 105637-50-1 | sc-200519 sc-200519A sc-200519B sc-200519C | 10 mg 50 mg 100 mg 250 mg | $112.00 $449.00 $673.00 $1224.00 | 2 | |
ML-9, a selective myosin light chain kinase (MLCK) inhibitor, indirectly influences claudin-2 by disrupting the MLCK signaling pathway. MLCK is involved in actin cytoskeleton remodeling and tight junction regulation. Inhibition of MLCK by ML-9 alters the dynamic regulation of claudin-2, impacting its localization and function within tight junctions. | ||||||
Caffeic acid phenethyl ester | 104594-70-9 | sc-200800 sc-200800A sc-200800B | 20 mg 100 mg 1 g | $71.00 $296.00 $612.00 | 19 | |
Caffeic acid phenethyl ester (CAPE), a natural polyphenol, indirectly modulates claudin-2 by targeting the nuclear factor-kappa B (NF-κB) signaling pathway. NF-κB is involved in inflammation and tight junction regulation. Inhibition of NF-κB by CAPE alters the expression and localization of claudin-2 within tight junctions. | ||||||
DIDS, Disodium Salt | 67483-13-0 | sc-203919A sc-203919B sc-203919 sc-203919C | 25 mg 100 mg 250 mg 1 g | $51.00 $163.00 $286.00 $683.00 | 6 | |
DIDS (4,4'-Diisothiocyanatostilbene-2,2'-disulfonic acid), an anion exchange inhibitor, indirectly influences claudin-2 by targeting ion transport pathways. DIDS inhibits anion transporters, affecting the paracellular permeability and localization of claudin-2 within tight junctions. | ||||||
Furosemide | 54-31-9 | sc-203961 | 50 mg | $41.00 | ||
Furosemide, a loop diuretic, indirectly influences claudin-2 by targeting the Na+-K+-2Cl- cotransporter (NKCC2). NKCC2 is involved in ion transport and tight junction regulation. Furosemide's inhibition of NKCC2 alters ion gradients, affecting the paracellular permeability and localization of claudin-2 within tight junctions. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002, a phosphoinositide 3-kinase (PI3K) inhibitor, indirectly influences claudin-2 by disrupting the PI3K pathway. PI3K is involved in tight junction regulation. LY294002's inhibition of PI3K alters the dynamic regulation of claudin-2, impacting its localization and function within tight junctions. | ||||||